CatenaBio

Berkeley, US · 3 known investors

Catena Biosciences develops therapeutics using its CysTyr conjugation platform to create Multi-Payload Conjugates (MPCs), a next-generation form of antibody-drug conjugate that delivers dual payloads. The company initially targets solid tumors with high unmet medical need.